Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: A five-yearlong experience

Journal of Headache and Pain

Volumn 7, Issue 6, 2006, Pages 407-412

  Farinelli, I ^a   Coloprisco, G ^a   Filippis, S ^a   Martelletti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Botulinum toxin type A; Chronic daily headache; Prophylaxis

Indexed keywords

ANTIDEPRESSANT AGENT; BONT A; BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC DAILY HEADACHE; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPHONIA; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MUSCLE RIGIDITY; NAUSEA; PRIORITY JOURNAL; PTOSIS; SKIN IRRITATION;

BOTULINUM TOXIN TYPE A; CHRONIC DISEASE; DRUG ADMINISTRATION ROUTES; FEMALE; HEADACHE DISORDERS; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33846136926     PISSN: 11292369     EISSN: 11292377     Source Type: Journal    
DOI: 10.1007/s10194-006-0344-9     Document Type: Article

References (43)

1. Linet MS, Celentano DD, Stewart WF (1991) Headache characteristics associated with physician consultation: A population-based survey. Am J Prev Med 7:40-46
2. Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J (2006) Epidemiology of headache in Europe. Eur J Neurol 13:333-345
3. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB (2003) The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 23:519-527
4. Lenaerts ME (2005) Pharmacoprophylaxis of tension-type headache. Curr Pain Headache Rep 9:442-447
5. Anand KS, Prasad A, Singh MM, Sharma S, Bala K (2006) Botulinum toxin type A in prophylactic treatment of migraine. Am J Ther 13:183-187
6. Bihari K (2005) Safety, effectiveness, and duration of effect of BONT-A after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm. Curr Med Res Opin 21:433-438
7. Leistad RB, Sand T, Westgaard RH, Nilsen KB, Stovner LJ (2006) Stressinduced pain and muscle activity in patients with migraine and tensiontype headache. Cephalalgia 26:64-73
8. Simpson LL (1980) Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 213:504-508
9. Simpson LL (2004) Identification of the major steps in Botulinum toxin action. Annu Rev Pharmacol Toxicol 44:167-193
10. Eleopra R, Tugnoli V, Rossetto O, De Grandis D, Montecucco C (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256:135-138
11. Durham PL, Cady R, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by Botulinum toxin type A: implications for migraine therapy. Headache 44:35-43
12. Durham PL (2006) Calcitonin generelated peptide (CGRP) and migraine. Headache 46[Suppl 1]:S3-S8
13. Caputi CA (2004) Effectiveness of BoNT-A in the treatment of migraine and its ability to repress CGRP release. Headache 44:837-838
14. Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW (2005) Duration of migraine is a predictor for response to Botulinum toxin type A. Headache 45:308-314
15. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L (2006) The effects of Botulinum Toxin type A on capsaicinevoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122:315-325
16. Headache Classification Committee of the International Headache Society (2004) The International Classification of Headache Disorders. Cephalalgia 24:1-160
17. Martelletti P (2006) The road ahead for chronic headache patients. J Headache Pain 7:317-319
18. Martelletti P (2002) The unfinished war. J Headache Pain 3:115-6
19. Martelletti P (2004) New migraine prophylaxis compounds from serendipity: Gambling or wisdom? J Headache Pain 5:169-170
20. Blumenfeld A (2004) Botulinum toxin type A for the treatment of headache: Pro. Headache 44:825-830
21. Welch KMA (2004) Botulinum toxin type A for the treatment of headache: con. Headache 44:831-833
22. Dodick DW, Mauskop A, Elkind AH, De Gryse R, Brin MF, Silberstein SD, BONT-A CDH Study Group (2005) Botulinum toxin type A for the prophylaxis of chronic daily headache: Subgroup analysis of patients not receiving other prophylactic medications: A randomized double-blind, placebo-controlled study. Headache 45:315-324
23. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, BONT-A CDH Study Group (2005) Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: A randomized, doubleblind, placebo-controlled trial. Headache 45:293-307
24. Relja M, Telarovic̀ S (2004) Botulinum toxin in tension-type headache. J Neurol 251[Suppl 1]:I13-I14
25. Blumenfeld A (2003) Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 43:853-860
26. Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R (2000) Treatment of tension-type headache with Botulinum toxin type A: A doubleblind, placebo-controlled study. Headache 40:300-305
27. Silberstein SD, Göbel H, Jensen R, Elkind AH, DeGryse R, Walcott JMCM, Turkel C (2006) Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: A multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 26:790-800
28. Evers S, Olesen J (2006) Botulinum toxin in headache treatment: The end of the road? Cephalalgia 26:769-771
29. Göbel H (2004) Botulinum toxin in migraine prophylaxis. J Neurol 251S:I8-I11
30. Boudreau G (2005) Treatment of chronic tension-type headache with botulinum toxin: A double-blind, placebo- controlled clinical trial. Cephalalgia 25:1101-1102
31. Troost BT (2004) Botulinum toxin type A (BOTOX) in the treatment of migraine and other headaches. Expert Rev Neurother 4:27-31
32. Conway S, Delplanche C, Crowder J, Rothrock J (2005) BoNT-A therapy for refractory chronic migraine. Headache 45:355-357
33. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A (2004) Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 24:838-843
34. Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM (2001) Effect of Botulinum toxin A in the treatment of chronic tension-type headache: A double- blind, placebo-controlled trial. Headache 41:658-664
35. Gupta VK (2005) Botulinum toxin type A therapy for chronic tension-type headache: Fact versus fiction. Pain 116:166-167
36. Schulte-Mattler WJ, Krack P (2005) Response to Gupta VK: Botulinum toxin type A for chronic tension-type headache: Fact versus fiction. Pain 116:167
37. Aurora S (2006) Botulinum toxin type A for the treatment of migraine. Expert Opin Pharmacother 7:1085-1095
38. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC, BOTOX-039 Study Group (2005) Botulinum toxin type A for the prophylactic treatment of chronic daily headache: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 80:1126-1137
39. Smuts JA, Schultz D, Barnard A (2004) Mechanism of action of Botulinum Toxin Type A in migraine prevention: A pilot study. Headache 44:801-805
40. Rozen D, Sharma J (2006) Treatment of tension-type headache with BOTOX: a review of the literature. Mt Sinai J Med 73:493-498
41. Mennini FS, Fioravanti L, Piasini L, Palazzo F, Coloprisco G, Martelletti P (2004) A one-year retrospective economic evaluation of Botulinum toxin type A treatment of chronic tension headache. J Headache Pain 5:188-191
42. Palazzo F, Mennini F, Fioravanti L, Piasini L, Coloprisco G, Martelletti P (2004) A one-year prospective costing study of botulinum toxin type A treatment of chronic tension headache. J Headache Pain 5:192-196
43. Coloprisco G, De Filippis S, Santi PG, Fiore G, Rodio A, Martelletti P (2003) Reduction in expenditures on analgesics during one year of treatment of chronic tension headache with BoNTA. J Headache Pain 4:88-91